Eloquent AI | $7,400,000 | (Sep 12, 2025)
Meela Inc. | $3,500,000 | (Sep 12, 2025)
TrustNXT | $1,874,888 | (Sep 12, 2025)
Sudo Biosciences
United States
- Menlo Park, California
- 21/12/2023
- Series B
- $116,000,000
Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives. Our lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.
- Industry Biotechnology Research
- Website https://www.sudobio.com/
- LinkedIn https://www.linkedin.com/company/sudo-biosciences/
Related People
Scott ByrdFounder
United States -
Zionsville, Indiana
Professional experience includes cross-functional roles across multiple therapeutic areas in the pharmaceutical industry: marketing, corporate strategy, commercial strategy, clinical development strategy, sales, hospital product sales and marketing, corporate finance, engineering, and manufacturing.
Specialties: Pharmaceutical marketing, pharmaceutical sales, hospital marketing, hospital sales, marketing strategy, coporate strategy, finance, pharmaceutical pricing reimbursement and access, pharmaceutical launch experience, cardiovascular, critical care, infectious disease.
Kriya Therapeutics, Inc. | $320,000,000 | (Sep 12, 2025)
Goodpath | $18,000,000 | (Sep 12, 2025)
BacAlt | $2,037,362 | (Sep 12, 2025)
Quack AI | $7,000,000 | (Sep 12, 2025)
Diana Health (We're Hiring!) | $55,000,000 | (Sep 12, 2025)
OpenHealth Technologies | $3,000,000 | (Sep 12, 2025)
Brain Co. | $30,000,000 | (Sep 12, 2025)
AegisAI Security | $13,000,000 | (Sep 12, 2025)
Clyx | $14,000,000 | (Sep 12, 2025)